Skip To Main Content
Alex Baras on Muck Rack

Alex Baras

As seen in: Nature, European Urology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Alex

Contact Alex, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Retraction Note: Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer

|
By Alok Singh, Monali Praharaj, Kara Lombardo, Takahiro Yoshida, Andres Matoso, Alex Baras, Liang Zhao, Geetha Srikrishna, Joy Huang, Pankaj Prasad Verified, Jonathan Powell, Max Kates, David J. McConkey, Drew Pardoll, William R Bishai, Trinity J. Bivalacqua
| Nature Verified
Retraction to: Nature Communications https://doi.org/10.1038/s41467-022-28509-z, published online 15 February 2022 The authors have retracted this article because there are duplicate cells in the Source Data for the following figure panels: Figure 1 panels d and e, Figure 2 panels a,b c and h, Figure 3 panels c and d, Figure 5 panel b, Figure 6 panels b and c, Figure 7 panels b, c and d, Figure S2 panels b, c and d, Figure S3 panel b, Figure S12, Figure S13 panels b, d and e, Figure S14...
Open in Who Shared View Duplicates (3) Issue with article?

Association between pathologic response and survival after neoadjuvant therapy in lung cancer - Nature Medicine

|
By Patrick M. Forde, Jonathan Spicer Verified, Robert A. Anders, Ludmila Danilova, Joel C. Sunshine, Judy Bushong, Tricia R. Cottrell, Alex Baras
| Nature Verified
Abstract Neoadjuvant immunotherapy plus chemotherapy improves event-free survival (EFS) and pathologic complete response (pCR, 0% residual viable tumor [RVT] in primary tumor [PT]+lymph nodes [LNs]), and is approved for treatment of resectable lung cancer. Pathologic response assessment after neoadjuvant therapy is the potential analog to radiographic response for advanced disease. However, %RVT thresholds beyond pCR and major pathologic response (≤10% RVT) have not been explored.
Open in Who Shared Issue with article?

Reply to Gopa Iyer, Bernard H. Bochner, Eliezer M. Van Allen, David B. Solit, and Jonathan E. Rosenberg's Letter to the Editor re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators o

|
By Russell Becker, Trinity J. Bivalacqua, Alex Baras
| European Urology Verified
We thank Iyer et al for their thoughtful commentary on our study [ 1 Becker REN, Meyer AR, Brant A, et al.;1; 2020 Clinical restaging and tumor sequencing are inaccurate indicators of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. In press.
Open in Who Shared View Duplicates (2) Issue with article?
See all 3 articles